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Background: Cerebral malaria (CM) is a clinical syndrome resulting from Plasmodium falciparum infection. A wide
range of clinical manifestations follow the disease including cognitive dysfunction, seizures and coma. CM
pathogenesis remains incompletely understood and without treatment this condition is invariably fatal. Artesunate
has been accepted as the most effective drug for treating severe malaria. Besides its antiparasitic activity, an
anti-inflammatory property has also been reported. In the current study, the immunomodulatory role of artesunate
was investigated using a Plasmodium berghei ANKA model of CM, trough evaluation of behavioural changes and
cytokines expression in hippocampus and in frontal cortex.
Methods: C57Bl/6 mice were infected with P. berghei by intraperitoneal route, using a standardized inoculation of
106 parasitized erythrocytes. Memory function was evaluated using the step-down inhibitory avoidance test. The
mRNA expression of IFN-γ, IL-1β, IL-6 and TNF in the frontal cortex and hippocampus of control and infected mice
on day 5 post-infection were estimated by quantitative real time PCR. Plasmodium berghei -infected mice also
received intraperitoneally a single dose of artesunate (32 mg/kg) on day 4 post-infection, and 24 hours after
treatment behavioural and immunological analysis were performed. The protein levels of cytokines IL-2, IL-6, IL-10,
IL-17, IFN-γ, TNF in the serum, frontal cortex and hippocampus of controls and P. berghei -infected mice treated or
not treated with artesunate were determined using a cytometric bead array (CBA) kit. The survival and neurological
symptoms of CM were also registered.
Results: CM mice presented a significant impairment of aversive memory compared to controls on day 5
post-infection. A higher mRNA expression of pro-inflammatory cytokines was found in the hippocampus and frontal
cortex of infected mice. A single dose of artesunate was also able to decrease the expression of inflammatory
cytokines in the hippocampus and frontal cortex of P. berghei-infected mice. In parallel, a significant improvement
in neurological symptoms and survival were observed in artesunate treated mice.
Conclusions: In summary, the current study provided further evidence that CM affects key brain areas related to
cognition process. In addition, different patterns of cytokine expression during the course of CM could be
modulated by a single administration of the anti-malarial artesunate.
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Cerebral malaria (CM) is a potentially reversible, diffuse
encephalopathy characterized mainly by the presence of
asexual forms of Plasmodium falciparum parasites in the
peripheral blood smears, and altered level of conscious-
ness in the absence of other causes of encephalopathy,
especially meningitis and viral encephalitis [1]. This con-
dition accounts for approximately 80% of all fatal cases
of malaria, being the leading cause of hospitalization and
mortality of children under five years of age in sub-
Saharan Africa [2,3]. A series of residual symptoms may
follow the resolution of CM including cognitive, behav-
ioural and motor changes [4]. Moreover, a significant so-
cial, economic and educational burden has been reported
in endemic areas of malaria [5].
Although vascular, immunological and metabolic
changes have been implicated in CM pathogenesis, it re-
mains largely unknown [6]. The obstruction of cerebral
microvasculature by sequestered infected red blood cells
and an exacerbation in host inflammatory response are
the two main non-exclusive theories widely accepted to
explain this pathological process [7].
The release of pro-inflammatory mediators, including
tumor necrosis factor (TNF) and interleukin (IL)-1, and
immune cells infiltration in the brain parenchyma have
been associated with cognitive and behavioural alter-
ations during the acute phase of experimental CM
[8-10]. However, it was only recently that a study con-
ducted by Linares et al. [11] suggested that the immune
response evoked by CM can specifically affect key brain
areas involved in the control of cognition and mnemonic
process, such as the hippocampus and the frontal cortex.
Without treatment CM invariably leads to death.
Emergency management is based on the correction of
metabolic states, re-establishment of vital physiological
functions severely affected by CM and the administra-
tion of an effective anti-parasitic drug [12].
Artesunate, a semi-synthetic derivative of artemisinin,
has been accepted as the most effective and safe drug for
treating severe and chloroquine-resistant malaria [13].
Besides its antiparasitic activity, artesunate has shown to
exhibit a putative anti-inflammatory profile in different
inflammatory models, including sepsis, arthritis, systemic
lupus erythematous and allergic asthma [14-18]. Clemmer
et al. [19] also demonstrated that artesunate was effective
in rescuing mice in a late-stage CM and that artemether,
another compound derivative of artemisinin, decreases
leukocyte accumulation in brain vessels. However, no pre-
vious study has investigated the immunomodulatory prop-
erties of artesunate in the central nervous system (CNS)
during the progression of CM.
The present study aimed to characterize the role of in-
flammatory mediated process within the hippocampus
and frontal cortex in the behavioural changes (memoryimpairment and sickness behaviour) induced by CM. In
addition, the putative immunomodulatory effect of a
single dose of artesunate was also investigated in the
experimental model of CM.
Methods
Ethics statement
This study was carried out in strict accordance with the
Brazilian Government’s ethical and animal experiments
regulations. The experimental protocol was approved by
the Committee on the Ethics of Animal Experiments of
the Universidade Federal de Minas Gerais (CETEA/
UFMG, Permit Protocol Number 105/09). All tissue-
collected procedures was performed under ketamine/
xylazine anesthesia and all efforts were made to minimize
animal suffering.
Animals
Female C57BL/6 mice (20-25 g), aged six to eight weeks,
were obtained from Animal Care Facilities of the Institute
of Biological Sciences, Federal University of Minas Gerais
(ICB-UFMG), Belo Horizonte, Brazil. The animals were
housed in groups of six mice per cage in a room
controlled temperature (24°C) with food and water ad
libitum. Experiments were performed on day 5 post-
infection (pi), when mice infected with Plasmodium
berghei strain ANKA develop brain inflammation with-
out motor impairment.
Parasite, experimental infection and artesunate treatment
Due to the high degree of reproducibility, easily manage-
able characteristics and development of histopathological
and neurological signs typical of human CM, the murine
model using the Plasmodium berghei strain ANKA has
been widely used to better understand this condition [20].
In the present study, blood stages of P. berghei strain
ANKA constitutively expressing green fluorescent protein
(P. berghei ANKA-GFP) (15cy1 clone), kindly provided by
Dr Claudio Marinho (Universidade de São Paulo), were
stored in liquid nitrogen [19]. Mice were infected intra-
peritoneally (ip) with 106 P. berghei-infected red blood
cells suspended in 0.2 mL PBS [21]. Artesunate (Sigma,
St. Louis, MO, USA) was dissolved in 5% sodium bicar-
bonate in saline and a single dose (32 mg/kg) was admin-
istered ip in the morning of the fourth day pi [19,22].
Control animals received the same volume of vehicle.
The percentage of parasitaemia was determined by
flow cytometry. Briefly, a drop of blood from the tail
was collected directly into 2 ml of PBS for flow cytome-
try analysis. Each sample was run on a FACScalibur
(Becton Dickinson, San Jose, CA, USA) flow cytometer
with a 488 nm argon laser and DIVA software (Becton
Dickinson, San Jose, CA, USA). Erythrocytes were iden-
tified on the basis of their specific forward (FSC) and





IFN-γ CAG GAT CCT TTG GAC
CCT CTG AC
GGC AGA ATT AAG CTT
ATT GGG AC
TNF-α ACG GCA TGG ATC TCA
AAG AC
AGA TAG CAA ATC GGC
TGA CG
IL-1β CTA CAG GCT CCG AGA
TGA ACA AC
TCC ATT GAG GTG GAG
AGC TTT C
IL-6 TTC CAT CCA GTT GCC TTC
TTG
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TCT GTG A
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100,000 events were counted for each sample. Mice
were observed daily for parasitaemia, body weight, sur-
vival, and clinical neurological signs of CM (i e, ataxia,
paralysis and coma).
Step-down inhibitory avoidance test
The step-down inhibitory avoidance test was performed to
assess short- and long-term aversive memory on day 5
and 6 post-infection (control and infected mice; n = 10 per
group) as previously described by Reis et al. [23]. Briefly,
in the training trial, animals were placed on the platform
and their latency to step down on the grid with all four
paws was measured. Immediately after the stepping down
on the grid, the animals received a single mild foot shock
(0.4 mA, 2.0 seconds). A retention test trial was performed
1.5 hour and 24 hours after the training section. The
results were expressed as latency period to step down the
platform, with a cut-off at 180 seconds. All tests were
performed by the same investigator who was blinded to
the animal status (control or infected).
Open field test
The open field test was performed as previously described
by Barichello et al. [24] and conducted in order to evaluate
the locomotor and exploratory activities on day 5 and 6 pi
of control and infected mice (n = 5 per group). The appar-
atus is a 30 cm× 30 cm circular open field surrounded by
30 cm-high walls made of transparent plexiglass (Insight®,
São Paulo, Brazil). The floor of the open field is divided in
12 rectangles by black lines. Briefly, animals were gently
placed on the left rear quadrant, and then they were
allowed to explore the arena for 5 minutes. The number
of crossings (the number of times that animals crossed the
black lines) and rearings (the exploration behaviour
observed in rats subjected to a new environment) were
recorded. Behavioural tests were performed by the same
investigator who was blinded to the animal status (control
or infected).
Rapid murine coma and behaviour scale (RMCBS)
Behavioural and functional parameters were evaluated
using the RMCBS protocol as previously described by
Carrol et al. [25]. The RMCBS is a quantitative and ob-
jective scale that enables an investigator to rapidly follow
up the course of CM. The subjects were labelled as af-
fected or not, and the levels of illness are correlated with
neuropathological injury. This method intended to imi-
tate the situation in the field and attempted to bring the
animal model closer to the human disease [25].
The RMCBS consists of ten parameters (gait, balance,
motor performance, body position, limb strength, touch
scape, pinna reflex, toe pinch, aggression and grooming)
based on the components of the SHIRPA (SmithKline/Harwell/Imperial College/Royal Hospital/Phenotype As-
sessment) score [26]. Each item is scored from zero as the
lowest, to two as the highest, with a maximum total score
of 20. The procedure was carried out on day 3 until day 5
pi. On day 5 pi the RMCBS were performed approxi-
mately 24 hours after artesunate treatment. A total of five
animals per group were used. After the test all animals
were sacrificed under deep anesthesia by ip injection of a
mixture of Ketamine (150 mg/kg, Laboratório Cristália,
Brazil) and Xylazine (10 mg/kg, Rompun®, Bayer,
Germany), decapitated, frontal cortex and hippocampal
dissected and serum collected for posterior cytokine
expression assessment.
Hippocampal and frontal cortex mRNA expression of
cytokines
The mRNA expression of IFN-γ, IL-1β, IL-6 and TNF in
the hippocampus and frontal cortex of P. berghei-infected
mice and matched controls (n = 5 per group) were esti-
mated by quantitative real time PCR (polymerase chain
reaction) at day 5 pi. RNA isolation was performed using
Illustra RNAspin Mini RNA Isolation Kit (GE Healthcare,
Little Chalfont, Buckinghamshire, UK). The RNA obtained
was re-suspended in diethyl pyrocarbonate-treated water
and stocked at -70°C until use. Reverse transcription was
performed using 2 μg of total RNA, 200 U of reverse
transcriptase, RT buffer 5 × (4 μl), 10 mM dNTPs (1 μl),
RNAsin 10,000 U (0.2 μl) and oligo dT 15 50 μM
(1.0 μl) in a final reaction volume of 20 μl. Resultant
cDNA was used for qPCR. Real-time RT-PCR was
performed on an ABI PRISM 7900 sequence-detection
system (Applied Biosystems, CA, USA) by using SYBR
Green PCR Master Mix (Applied Biosystems, CA, USA)
after a reverse transcription reaction of 2 μg of total
RNA by using M-MLV reverse transcriptase (Promega,
Madison, Wisconsin-WI, USA). Specific primers were
designed using Primer Express software and synthesized
by integrated DNA technologies (IDT). The relative
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Cycle threshold method as described by the manufac-
turer, in which data for each sample is normalized to
18S expression and data were shown as fold increase
over the negative control (non-infected) group. Specific
primers sequences are described in Table 1.
Cytometric bead array (CBA) and enzyme-linked
immunosorbent assay (ELISA) analyses of cytokines
Hippocampal and frontal cortex tissues of controls (n =
5 per group) and P. berghei-infected mice treated or notFigure 1 Short-term aversive memory impairment without locomotor
infection. Aversive memory, locomotor and exploratory activities measurem
of control group in the step-down inhibitory avoidance test (a-c) and in th
in the step-down inhibitory avoidance test; (b) Short-term memory analyse
test; (c) Long-term memory analysed 24 hours (6 pi) after training session i
and (e) number of rearing episodes analysed on day 5 post-infection in th
representative of two independent experiments. Asterisk(s) indicate statistictreated (n = 5 per group) with a single dose of artesunate
were carefully removed on day 5 pi and homogenized in
a PBS-buffer extraction solution containing a protease-
inhibitor cocktail. Lysates were centrifuged at 13,000 g
for 10 minutes at 4°C and quantified using the Bradford
assay reagent from Bio-Rad (Hercules, CA, USA). Ana-
lyses of serum and brain cytokine levels were determined
using a mouse Th1/Th2/Th17 cytometric bead array kit
(CBA; BD Biosciences, San Diego, CA, USA) and analysed
on a FACSCalibur flow cytometer (Becton Dickinson, San
Jose, CA, USA). The following cytokines were measured:and exploratory changes following Plasmodium berghei ANKA
ent of P. berghei-infected mice on day 5 and 6 post-infection (pi) and
e open field (d-e). (a) Latency in seconds during training session (5 pi)
d 1.5 hours after training session in the step-down inhibitory avoidance
n the step-down inhibitory avoidance test; (d) number of crossings
e open field. Results are expressed as mean ± SEM and are
al differences, *p < 0.05.
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(IL-10), interleukin-17 (IL-17), Interferon-γ (IFN-γ) and
tumor necrosis factor-α (TNF). The concentration of the
cytokine IL-1β was determined by ELISA (R&D Systems,
Minneapolis, MN, USA) in accordance with manufac-
turer’s instructions.
Data analysis and statistical evaluation
Results obtained were presented as mean ± standard error
of the mean (SEM). All data were tested for normality
(Kolmorov-Smirnov’s test) and homogeneity of variances
(Levene’s test). For variables normally distributed and with
compliance of homogeneity of variances, differences were
compared by using Student’s t test, analysis of variance
(ANOVA) or Two-way ANOVA. Duncan’s post-test was
used as needed for multiple comparisons. In the case of
variables not normally distributed, differences were ana-
lysed by Kruskal-Wallis non-parametric test. When signifi-
cant effects were detected by this latter test, post-hoc
comparisons were performed using the Mann-Whitney U
test. Differences between lethality curves were calculated
using the Log rank test. The significance level was set at
the level of p < 0.05. Statistical analyses were performedFigure 2 Frontal cortex and hippocampus mRNA expression of pro-in
infection. C57BL/6 mice were intraperitoneally infected with 106 parasitize
volume of PBS (n = 5 per group). On day 5 post-infection (5 dpi) frontal cor
use arbitrary units for the ratio of the target gene mRNA to the endogenou
**p < 0.01, ***p < 0.001.using Prism 4 software (GraphPad, La Jolla, CA, USA) and
SPSS software version 17.0 (SPSS Inc, Chicago, IL, USA).
Results
Plasmodium berghei-infected mice exhibited short-term
aversive memory impairment
Figure 1 shows the effect of P. berghei infection in the step-
down inhibitory avoidance test and open field test. No
difference in the step-down latency between P. berghei-
infected mice and controls was found in the training
session (Figure 1a). In the test session performed 1.5 hours
after the training to evaluate the short-term aversive mem-
ory, infected mice presented a significant decrease in the
step-down latency (Figure 1b; p = 0.03). No difference was
found in the long-term aversive memory analysed 24 hours
(day 6 pi) after training session (Figure 1c; p = 0.99).
In the open field test, there were no significant differ-
ences in the number of crossings (Figure 1d; p = 0.89)
and rearings (Figure 1e; p = 0.91) in the P. berghei-
infected group compared to the controls on day 5 pi,
indicating no difference in motor and exploratory activ-
ities, respectively. However, on day 6 pi, the period when
the long-term memory was assessed, P. berghei-infectedflammatory cytokines following Plasmodium berghei ANKA
d erythrocytes and control (non-infected) animals received the same
tex and hippocampus were collected for real time PCR analysis. Results
s control, eukaryotic 18SmRNA. Statistical significance: *p < 0.05,
Figure 3 (See legend on next page.)
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Figure 3 Cytokine levels in the frontal cortex of controls and infected mice following artesunate treatment. C57BL/6 mice were
intraperitoneally infected with 106 parasitized erythrocytes and control (non-infected) animals received the same volume of PBS (n = 5 per group).
On day 4 post-infection P. berghei-infected (mice received a single dose of artesunate (ip 32 mg/kg). The frontal cortex was collected on day 5
post-infection, homogenized and IL-1β expression was measured by ELISA while IFN-γ, TNF-α, IL-2, IL-4, IL-6, IL-10 and IL-17 levels were assessed
by cytometric bead array (CBA). Results are expressed as mean ± SEM. Asterisk(s) indicate statistical differences, *p <0.05.
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and exploratory (p = 0.002) activities (data not shown).
Inflammatory changes in hippocampus and frontal cortex
of P. berghei-infected mice, key areas related to memory
and learning
In order to evaluate inflammatory parameters in specific re-
gions well known to participate in memory formation and
consolidation, the mRNA expression of IFN-γ, TNF, IL-1β
and IL-6 and the protein levels of IFN-γ, TNF, IL-1β, IL-2,
IL-4, IL-6, IL-10 and IL-17 was analyzed in hippocampus
and frontal cortex of controls and P. berghei-infected mice
on day 5 pi.
The mRNA expression of TNF and IL-1β was signifi-
cantly increased in the frontal cortex and hippocampus
of P. berghei-infected mice compared to controls. A
higher mRNA expression of IFN-γ and IL-6 was only
observed in the hippocampus of P. berghei-infected mice
(Figure 2).
Regarding protein levels, a significant increase of TNF,
IL-1β and IFN-γ was found in the frontal cortex of infected
animals, whereas a reduction of IL-10 was also observed
(Figure 2). In the hippocampus higher levels of IL-1β, IL-6
and IFN-γ were found on day 5 pi in parallel with a de-
crease in IL-2 expression (Figure 3). No significant differ-
ences were detected in the levels of IL-2, IL-4, IL-6 and
IL-17 in the frontal cortex, and in the levels of IL-4, IL-10,
IL-17 and TNF in the hippocampus when comparing
controls and P. berghei-infected animals (Figures 3 and 4).
A single dose of artesunate reduced cytokines levels in
the hippocampus and frontal cortex of P. berghei-infected
mice
The putative anti-inflammatory property of artesunate
has been demonstrated in different conditions [17,18].
To investigate its effects in CM, the cytokine levels in
frontal cortex, hippocampus and serum of controls and
P. berghei-infected mice that received or not a single
dose of artesunate were assessed.
PbA-infected mice presented an increase in frontal cortex
levels of TNF (F(2,12) = 3.8; p < 0.05), IFN-γ (F(2,12) = 7.1;
p < 0.01) and IL-1β (F(2,12)= 3.6; p < 0.05), and decreased
levels of IL-10 (F(2,12) = 3.1; p < 0.05) in comparison with
controls (Figure 3). The levels of cytokines of infected mice
treated with artesunate in the frontal cortex were similar to
controls (Figure 3). Plasmodium berghei-infected mice
showed an increase in hipoccampal levels of IFN-γ (F(2,12) =7.7; p < 0.01) and IL-6 (F(2,12) = 5.91; p < 0.05), and decreased
levels of IL-2 (F(2,12) = 8.6; p < 0.01) in comparison with
controls and treated P. berghei-infected mice (Figure 4). No
significant difference was found in serum cytokine levels
between treated and non-treated P. berghei-infected
groups. When compared to the controls they exhibited
higher serum levels of IL-6 (χ2(df = 2, n = 15) = 9.5, p <
0.05, control versus P. berghei, U = 0; z = -2.6,p < 0.05; con-
trol versus P. berghei + artesunate U = 0; z = 2.,6; p < 0.05),
IFN-γ (χ2(df = 2, n = 15) = 10.5, p < 0.05, control versus P.
berghei, U = 0; z = -2.6,p < 0.05; control versus P. berghei +
artesunate U = 0;z = 2.,6, p < 0.05) and TNF (χ2(df = 2, n =
15) =10.8, p < 0.05, control versus P. berghe, U = 0; z = -2.6,
p < 0.05; control versus P. berghei + artesunate U = 0; z =
2.6, p < 0.05) than controls (Figure 5).
A single dose of artesunate improved survival and clinical
signs of cerebral malaria
Plasmodium berghei -infected mice treated with a single
dose of artesunate presented a significant improvement
in survival (χ2 = 8.5, p < 0.001; Figure 6a) and a decrease
in the percentage of parasitaemia on day 5 pi when
compared with non-treated infected animals (Figure 6b).
While P. berghei-infected mice presented significant
changes in clinical parameters assessed by RMCBS,
treated mice did not show clinical symptoms of CM
(Figure 6c). Both treated and non-treated P. berghei-
infected mice lost weight, but it was more significant in
non-treated mice at day 5 pi (Figure 6d).
Discussion
In the present study, short-term aversive memory impair-
ment was associated with increased levels of pro-
inflammatory cytokines and decrease of regulatory media-
tors, such as IL-2 and IL-10, in the hippocampus and
frontal cortex of P. berghei-infected mice. Therefore, differ-
ent patterns of cytokines expression seem to be dependent
on the region assessed, i e, hippocampus or frontal cortex.
This study investigated the expression (mRNA and pro-
tein) of cytokines in memory-related areas during CM, and
the results reinforce a role for inflammation in the devel-
opment and persistence of cognitive changes.
Inflammatory processes in the CNS, including an up-
regulation of pro-inflammatory cytokines, have been as-
sociated with cognitive and behavioural dysfunctions in
clinical and experimental CM. For instance, a previous
study demonstrated that P. berghei-infected mice exhibit
Figure 4 (See legend on next page.)
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Figure 4 Cytokine levels in the hippocampus of controls and infected mice following artesunate treatment. C57BL/6 mice were
intraperitoneally infected with 106 parasitized erythrocytes and control (non-infected) animals received the same volume of PBS (n = 5 per group).
On day 4 post-infection P .berghei-infected mice received a single dose of artesunate (ip 32 mg/kg). The hippocampus was collected on day 5
post-infection, homogenized and IL-1β expression was measured by ELISA while IFN-γ, TNF, IL-2, IL-4, IL-6, IL-10 and IL-17 levels were assessed by
cytometric bead array (CBA). Results are expressed as mean ± SEM. Asterisk(s) indicate statistical differences where *p < 0.05.
Miranda et al. Malaria Journal 2013, 12:388 Page 9 of 13
http://www.malariajournal.com/content/12/1/388anxiety-like symptoms associated with increased brain
levels of IL-1β and TNF, and histopathological changes
in brainstem, cerebrum and hippocampus [10]. Desruis-
seaux et al. [8] found a significant impairment in work-
ing memory of PbA-infected mice, which was associated
with cell infiltration and haemorrhage in thalamus, mid-
brain and cerebellum and with microglial activation in
the cortex and hippocampus. Additionally, John et al.
[27] have suggested a negative correlation between cog-
nitive (attention and working memory) deficits and cere-
brospinal fluid (CSF) levels of TNF in children with CM.
Although these experimental and human studies have
provided evidence for the role of altered levels of cyto-
kines in cognitive and behavioural changes found in
CM, few studies investigated the expression of cytokines
in specific brain areas, such as hippocampus and frontal
cortex, involved in these functions.
A recent study conducted by Linares et al. [11] demon-
strated an increase in IFN-γ and TNF mRNA expression
in several brain areas of P. berghei-infected mice, including
cortex, hippocampus, thalamus/hypothalamus and brain-
stem. The upregulation of these cytokines was found in an
early or asymptomatic stage of CM and was associated
with an increased expression of immunoproteasome sub-
units. The replacement of proteasome subunits for immu-
noproteasome factors is a brain-inflammatory response
that inhibits normal protein turnover [28]. There is evi-
dence that proteasome also participates in neuronal sur-
vival and plasticity [29]. The substitution of proteasome
for immunoproteasome complex could lead to neuronal
death contributing to the cognitive deficits through im-
pairment of synaptic function [28,30]. The present study
provides evidence that pro-inflammatory cytokines ex-
pression remain upregulated in the hippocampus and
frontal cortex until symptomatic stage of CM, culminating
with cognitive impairment. It is worth mentioning that no
impairment was found in long-term aversive memory,
probably due to significant locomotor and exploratory def-
icits observed on day 6 pi. In agreement, previous studies
have been demonstrated that changes in motor activity
during CM occurred on day 6 p.i. whereas anxiety like
behaviour appeared earlier on day 5 pi [10,31]. Thus, it
seems that behavioural disorders precede locomotor im-
pairment during neuroinflammation caused by P. berghei
ANKA infection.
CM is a clinical emergence that is invariably fatal with-
out appropriate treatment [12]. Artesunate is a potentanti-malarial drug which has been widely accepted as
the treatment of choice for severe malaria [13]. Apart
from its well-known antiparasitic property, there is
growing evidence suggesting an immunomodulatory
activity of artesunate in infectious and autoimmune
disorders [14-18]. Artesunate was able to protect mice
subjected to sepsis by decreasing serum IL-6 and TNF
levels via inhibition of Toll-like receptors expression and
NF-κB activation in peritoneal macrophages [17,32,33].
In a rat model of arthritis, artesunate treatment signifi-
cantly attenuated inflammation and cartilage damage by
decreasing the levels of IL-1β, IL-17 and TNF in rat’s
hind paws. The anti-arthritic effect of artesunate was
associated with NF-κB and mitogen-activated protein
kinase signaling pathway suppression [18]. A decrease in
cytokine levels and oxidative stress in lung tissue was
also found in an allergic asthma model after artesunate
treatment [14,15]. Altogether these studies provide
strong evidence of artesunate capacity of modulating in-
flammatory response through the regulation of signaling
pathways.
No previous study investigated the effect of artesunate
in the CNS inflammation during CM. In the present
study, a single dose of artesunate was able to decrease
pro-inflammatory cytokines expression in the hippocam-
pus and frontal cortex of P. berghei-infected mice in par-
allel with a significant reduction of parasitaemia and
improvement in neurological symptoms and survival.
A single dose of artesunate was highly effective in
clearing P. berghei parasitaemia at day 5 pi, rescuing
mice in the late stages of CM. Reduction of the number
of adherent leukocytes in brain vessels of P. berghei-
infected mice was also observed 24 hours after a single
dose of artemether [19]. These authors suggested that the
decrease in brain inflammatory response could be a conse-
quence of faster parasitaemia clearance associated with an
intrinsic anti-inflammatory property presented by artemisi-
nin derivatives [19]. Interestingly, a systemic release of pro-
inflammatory cytokines during the acute phase of malaria
is required for the control of parasitaemia [34]. Moreover,
the serum levels of cytokines (IL-6, IFN-γ and TNF) in
P. berghei-infected mice treated with artesunate were
comparable to non-treated P. berghei-infected animals.
An in vitro study conducted by Lee et al. [35] showed
that artesunate attenuates LPS-induced inflammatory
responses in microglial BV2 cells by activating the Nrf2
transcription factor NF-E2-related factor-2 (Nrf2). This
Figure 5 (See legend on next page.)
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Figure 5 Cytokine levels in the serum of controls and infected mice following artesunate treatment. C57BL/6 mice were
intraperitoneally infected with 106 parasitized erythrocytes and control (non-infected) animals received the same volume of PBS (n = 5 per
group). On day 4 post-infection P. berghei-infected mice received a single dose of artesunate (ip 32 mg/kg). The serum was collected at day 5
post-infection and IFN-γ, TNF, IL-2, IL-4, IL-6, IL-10 and IL-17 levels were assessed by cytometric bead array (CBA). Results are expressed as mean
± SEM. Asterisk(s) indicate statistical differences. *p < 0.05.
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http://www.malariajournal.com/content/12/1/388transcription factor regulates inflammatory responsive-
ness in the CNS by mediating the expression of import-
ant antioxidant and phase II detoxification genes, and
leading to an increase in the level of haem oxygenase-1
[35]. There is evidence that haem oxygenase-1 suppress
the pathogenesis of experimental CM by preventing
blood-brain barrier disruption, brain microvasculature
congestion and neuro-inflammation [36,37]. The current
study provided evidence of an anti-inflammatory role of
artesunate in the CNS of P. berghei-infected mice indi-
cating that CM symptoms prevention was not only due
to parasitaemia clearance.
Experimental cerebral malaria development is dependent
of Plasmodium strains and mice of susceptible genetic
background. In systemic models of malaria, infected mice
did not present CNS inflammation as well as CM signs but
rather a significant increase in parasitemia and anemia.
The lack of cognitive and neurological impairment after
parasitemia clearance by chloroquine in those models sup-
ports a specific CNS involvement in CM outcome rather
than severe systemic disease or the presence of the parasite
per se [23]. A recent study conducted by Reis et al. [38]
demonstrated that the statin Lovastatin (which exhibits a
significant anti-inflammatory effect) was capable of de-
creasing pro-inflammatory cytokine levels in CNS duringFigure 6 A single dose of artesunate improved survival and clinical signs
mice treated or not treated with artesunate were expressed days after infectio
cytometric analysis; (c) clinical signs of cerebral malaria assessed by the RMCB
treated with artesunate. The data is representative of two independent experi
indicate statistical differences, *p < 0.05.the acute phase of CM without influencing parasit-
aemia. However, improvement in survival rate was only
observed in association with the antimalarial chloro-
quine. Despite being highly effective in preventing mor-
tality, chloroquine alone did not prevent CM cognitive
and behavioral outcome. This indicates that limiting the
inflammatory damage to the brain is necessary to improve
CM outcome in addition to an effective control of the
parasitic disease. P. berghei ANKA mice were also treated
with sodium diclofenac or allopurinol as control anti-
inflammatory agents and did not detect protective effects
in CM. In fact, sodium diclofenac increased mortality in
infected animals, suggesting that anti-inflammatory drugs
could trigger distinct immunomodulatory effects which
could be effective or not to improve CM outcome [38].
Conclusion
In summary, the present study provided further evidence
that key areas related to memory, such as hippocampus
and frontal cortex, presented different patterns of cytokine
expression. Furthermore, it seems that the anti-malarial
artesunate presented not only a systemic antiparasitic
activity but could also regulate inflammatory responses in
the CNS by decreasing local pro-inflammatory cytokines
release during the course of CM. As this study is largelyof cerebral malaria. (a) Survival curve comparisons of P. berghei-infected
n; (b) natural course of P. berghei infection was determined by flow
S scale; (d) weight variation in P. berghei-infected mice treated or not
ments (n = 5 per group) and shown as the mean+/- SEM. Asterisk(s)
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http://www.malariajournal.com/content/12/1/388descriptive, further studies are required to systematically
investigate the immune/inflammatory pathways involved
in the anti-inflammatory activity of artesunate in CM as
well as its impact on cognitive outcome. Moreover, other
symptoms typical of infection conditions such as fever
should be also evaluated in association with parasitemia,
body weight loss and clinical neurological signs of CM
(ataxia, paralysis and coma) to determine the progression
of the disease as well as to guide antimalarial treatment.
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